What Is the Latest Real-World Evidence With CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer?
Manage episode 356746208 series 3381434
Tekijältä ReachMD. Player FM:n ja yhteisömme löytämä — tekijänoikeuksien omistajana on kustantaja eikä Player FM ja ääntä lähetetään suoraan heidän palvelimiltaan. Napsauta Tilaa -painiketta, kun haluat seurata Player FM:n päivityksiä tai liittää syötteen URL-osoitteen muihin podcast-sovelluksiin.
CME credits: 0.75
Valid until: 10-02-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-latest-real-world-evidence-with-cdk46-inhibitors-in-metastatic-hr-breast-cancer/14783/
The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors has drastically changed the treatment landscape of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer. In clinical studies, combination regimens with CDK4/6 inhibitors consistently double progression-free survival compared to endocrine therapy alone. The impact on overall survival data, however, has been less consistent thus far, with some agents showing a greater benefit than others. This program discusses the real-world survival benefit and tolerability of CDK 4/6 inhibitors in patients with HR+/HER2- breast cancer. Clinicians will gain a broader understanding of how these therapies work in patients and obtain access to a patient education tool that will help inform shared decision-making between patients and providers.
…
continue reading
Valid until: 10-02-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-latest-real-world-evidence-with-cdk46-inhibitors-in-metastatic-hr-breast-cancer/14783/
The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors has drastically changed the treatment landscape of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer. In clinical studies, combination regimens with CDK4/6 inhibitors consistently double progression-free survival compared to endocrine therapy alone. The impact on overall survival data, however, has been less consistent thus far, with some agents showing a greater benefit than others. This program discusses the real-world survival benefit and tolerability of CDK 4/6 inhibitors in patients with HR+/HER2- breast cancer. Clinicians will gain a broader understanding of how these therapies work in patients and obtain access to a patient education tool that will help inform shared decision-making between patients and providers.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
983 jaksoa
Jaa
))
